Form S-3ASR 4D Molecular Therapeutic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Goldman Sachs Reinstates 4D Molecular Therapeutics (FDMT) at Buy, 'Platform value to inflect via 2024 catalysts'
February 7, 2024 4:53 AM EST(Updated - February 7, 2024 5:21 AM EST)
Goldman Sachs analyst Salveen Richter reinstates coverage on 4D Molecular Therapeutics (NASDAQ: FDMT) with a Buy rating and a price target of $81.00.
The analyst comments "Given positive Ph2 intravitreal gene therapy 4D-150 data in wet age-related macular degeneration (wAMD), and the planned Ph3 initiation in 1Q25, we move from Not... More
4D Molecular Therapeutics Inc. (FDMT) Files Mixed Shelf
February 5, 2024 4:38 PM EST4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
... More4D Molecular Therapeutics Inc. (FDMT) Files Mixed Shelf
February 5, 2024 4:38 PM EST4D Molecular Therapeutics Inc. (NASDAQ: FDMT) has filed mixed shelf of:
Common Stock
Preferred Stock
Debt Securities
Warrants
Units
... More